- li>
- li>
- li>
- li>
- li>
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | 0.00 | 0.00 | 0.00 |
| EPS, GAAP | 0.00 | 0.00 | 0.00 |
| Consensus Estimate | 0.00 | 0.00 | 0.00 |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | 0.00 | 0.00 | 0.00 |
| EPS, GAAP | 0.00 | 0.00 | 0.00 |
| Consensus Estimate | 0.00 | 0.00 | 0.00 |
| FMS | Industry Average | |
| P/E (TTM) | 16.64 | NA |
| P/E (Forward) | 0.00 | NA |
| PEG Ratio | 0.00 | 0.00 |
| Price/Sales | 0.00 | 0.00 |
| Beta | 0.00 | 0.00 |
| 7:58 AM | 4/26/2012 | 2nd UPDATE: Fresenius SE Offers EUR3.1 Billion For Rhoen-Klinikum |
| 5:00 AM | 4/26/2012 | UPDATE: Fresenius SE Offers EUR3.1 Billion For Rhoen-Klinikum |
| 3/28/2012 | Affymax gets Omontys approved, and the battle with Amgen begins. (The Motley Fool) |
![[sm061210things]](http://s.wsj.net/public/resources/images/PF-AC562_sm0612_C_20120514113337.jpg)
![[sm0612wedding4]](http://s.wsj.net/public/resources/images/PF-AC579_sm0612_C_20120515172853.jpg)
![[sm0612strat]](http://s.wsj.net/public/resources/images/PF-AC580_sm0612_C_20120515180019.jpg)
![[sm0612roi]](http://s.wsj.net/public/resources/images/PF-AC573_sm0612_C_20120515125902.jpg)